As of 2024-12-12, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -9.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 34.70 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -3.66 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 20.0x | 16.6x |
| Forward P/E multiples | 13.3x - 20.0x | 16.6x |
| Fair Price | (0.41) - (0.61) | (0.51) |
| Upside | -257.6% - -332.8% | -295.2% |
| Date | EV/EBITDA |
| 2024-11-29 | -10.16 |
| 2024-11-28 | -9.82 |
| 2024-11-27 | -10.16 |
| 2024-11-26 | -9.82 |
| 2024-11-25 | -10.33 |
| 2024-11-22 | -10.16 |
| 2024-11-21 | -9.82 |
| 2024-11-20 | -9.82 |
| 2024-11-19 | -8.80 |
| 2024-11-18 | -9.14 |
| 2024-11-15 | -9.82 |
| 2024-11-14 | -10.16 |
| 2024-11-13 | -10.33 |
| 2024-11-12 | -9.65 |
| 2024-11-11 | -9.65 |
| 2024-11-08 | -9.99 |
| 2024-11-07 | -10.50 |
| 2024-11-06 | -10.16 |
| 2024-11-05 | -9.99 |
| 2024-11-04 | -10.16 |
| 2024-11-01 | -10.33 |
| 2024-10-31 | -9.82 |
| 2024-10-30 | -10.16 |
| 2024-10-29 | -10.67 |
| 2024-10-28 | -10.84 |
| 2024-10-25 | -8.97 |
| 2024-10-24 | -8.80 |
| 2024-10-23 | -9.31 |
| 2024-10-22 | -9.48 |
| 2024-10-21 | -9.99 |
| 2024-10-18 | -9.14 |
| 2024-10-17 | -7.78 |
| 2024-10-16 | -8.12 |
| 2024-10-15 | -7.44 |
| 2024-10-11 | -7.27 |
| 2024-10-10 | -7.44 |
| 2024-10-09 | -8.29 |
| 2024-10-08 | -7.95 |
| 2024-10-07 | -8.12 |
| 2024-10-04 | -7.78 |
| 2024-10-03 | -6.93 |
| 2024-10-02 | -7.61 |
| 2024-10-01 | -7.10 |
| 2024-09-30 | -6.41 |
| 2024-09-26 | -5.73 |
| 2024-09-24 | -5.73 |
| 2024-09-23 | -5.73 |
| 2024-09-20 | -5.73 |
| 2024-09-19 | -5.73 |
| 2024-09-18 | -5.73 |